Epithelial Ovarian Cancer Global Market Report 2025

Description

Epithelial ovarian cancer (EOC) is the most common form of ovarian cancer, originating from the epithelial cells that make up the outer layer of the ovary. It typically affects women over the age of fifty and is often asymptomatic in the early stages, resulting in late-stage diagnoses when the cancer has already progressed. When symptoms do appear, they may include abdominal bloating, pelvic pain, frequent urination, and changes in bowel movements.

The main treatment options for epithelial ovarian cancer include chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and surgery. Chemotherapy involves the use of drugs to kill or slow the growth of cancer cells, with options such as platinum-based drugs, poly(adp-ribose) polymerase inhibitors, bevacizumab, and other chemotherapeutic agents. Chemotherapy is used in both early and advanced stages of the disease. Diagnosis can be made through imaging, biopsies, and blood tests, and the treatment is commonly administered in hospitals, clinics, and diagnostic laboratories.

The epithelial ovarian cancer market research report is one of a series of new reports from The Business Research Company that provides epithelial ovarian cancer market statistics, including epithelial ovarian cancer industry global market size, regional shares, competitors with a epithelial ovarian cancer market share, detailed epithelial ovarian cancer market segments, market trends and opportunities, and any further data you may need to thrive in the epithelial ovarian cancer industry. This epithelial ovarian cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The epithelial ovarian cancer market size has grown rapidly in recent years. It will grow from $2.08 billion in 2024 to $2.42 billion in 2025 at a compound annual growth rate (CAGR) of 16.5%. The growth during the historical period can be attributed to factors such as the increasing demand for personalized cancer treatments, rising global healthcare spending, a growing preference for minimally invasive surgeries, a higher number of ovarian cancer survivors, increased demand for gene therapies, and a rise in the need for palliative care services.

The epithelial ovarian cancer market size is expected to see rapid growth in the next few years. It will grow to $4.41 billion in 2029 at a compound annual growth rate (CAGR) of 16.1%. In the forecast period, growth is expected due to the increasing incidence of ovarian cancer, an aging population, greater awareness of ovarian cancer, more research funding for cancer, and growing government initiatives aimed at combating cancer. Key trends during this period include technological advancements in medical imaging, the introduction of new molecular diagnostic tools, collaborations between pharmaceutical companies, the rapid adoption of AI and machine learning in diagnostics, and a growing use of robotic surgeries.

The growing incidence of ovarian cancer is expected to drive the expansion of the epithelial ovarian cancer market in the coming years. Ovarian cancer begins in the ovaries, primarily affecting the epithelial cells that line their surface. This increase in prevalence is largely attributed to an aging population, better awareness, improved detection rates, and factors such as genetics and lifestyle. Treatment for epithelial ovarian cancer is essential in addressing this common and aggressive form of the disease, targeting malignant cells to enhance survival and patient outcomes. According to the World Ovarian Cancer Coalition, a non-profit organization based in Canada, the global number of women diagnosed with ovarian cancer is projected to rise by over 55% by 2050, reaching 503,448. Additionally, annual deaths from ovarian cancer are expected to increase by nearly 70% from 2022, reaching 350,956. As a result, the growing prevalence of ovarian cancer will propel the market for epithelial ovarian cancer treatments.

Leading companies in the epithelial ovarian cancer market are focusing on developing cutting-edge treatment solutions, such as FRa-directed antibody-drug conjugates (ADCs), which target the folate receptor-alpha overexpressed on cancer cells. These treatments deliver potent cytotoxic agents directly to the cancer cells, while minimizing damage to healthy tissues. For example, in November 2024, AbbVie Inc., a biopharmaceutical company based in the United States, received European Commission approval for ELAHERE (mirvetuximab soravtansine). This targeted therapy is designed for adult patients with FRa-positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. ELAHERE offers an effective treatment option for patients who have undergone up to three prior systemic regimens. By targeting a biomarker present in about one-third of ovarian cancer patients, it improves survival prospects and enhances the patient's quality of life. The approval also includes a companion diagnostic to help identify eligible patients.

In February 2024, AbbVie Inc. acquired ImmunoGen in a deal worth $10.1 billion to expand its oncology portfolio. This acquisition brings ELAHERE, a targeted antibody-drug conjugate for treating platinum-resistant ovarian cancer, into AbbVie's offerings. The move aims to reduce reliance on older drugs and position AbbVie within the growing ADC market. ImmunoGen, a US-based manufacturer, specializes in drugs for epithelial ovarian cancer.

Major players in the epithelial ovarian cancer market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck KGaA, Siemens Healthineers AG, Quest Diagnostics Incorporated, Eisai Co. Ltd., Genentech Inc., Qiagen N.V., Myriad Genetics Inc., Zymeworks Inc., Novogen Limited, Karyopharm Therapeutics Inc., Clovis Oncology Inc., ImmunoGen Inc., Fujirebio Diagnostics Inc., and Vivesto AB.

North America was the largest region in the epithelial ovarian cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in epithelial ovarian cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the epithelial ovarian cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The epithelial ovarian cancer market consists of revenues earned by entities by providing services such as genetic testing, supportive care services, telemedicine, and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The epithelial ovarian cancer market also includes sales of diagnostic kits, targeted therapy drugs, chemotherapeutic agents, surgical instruments, and devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Epithelial Ovarian Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on epithelial ovarian cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for epithelial ovarian cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The epithelial ovarian cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type Of Treatment: Chemotherapy; Targeted Therapy; Immunotherapy; Hormonal Therapy; Surgery
2) By Drug Class: Platinum-based Chemotherapy Drugs; Poly(ADP-ribose) Polymerase Inhibitors; Bevacizumab; Chemotherapeutic Agents
3) By Stage Of Cancer: Early Stage; Advanced Stage
4) By Diagnosis Method: Imaging; Biopsy; Blood Tests
5) By End User: Hospitals; Clinics; Diagnostic Laboratories
Subsegments:
1) By Chemotherapy: Platinum-Based Chemotherapy; Non-Platinum Chemotherapy; Combination Chemotherapy
2) By Targeted Therapy: Monoclonal Antibodies; PARP Inhibitors; Angiogenesis Inhibitors; Other Targeted Agents
3) By Immunotherapy: Checkpoint Inhibitors; Cancer Vaccines; Adoptive T-Cell Therapy
4) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Progestins
5) By Surgery: Debulking Surgery; Oophorectomy; Hysterectomy; Other Surgical Procedures
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33708

1. Executive Summary

2. Epithelial Ovarian Cancer Market Characteristics

3. Epithelial Ovarian Cancer Market Trends And Strategies

4. Epithelial Ovarian Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Epithelial Ovarian Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global Epithelial Ovarian Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Epithelial Ovarian Cancer Market Growth Rate Analysis
5.4. Global Epithelial Ovarian Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Epithelial Ovarian Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Epithelial Ovarian Cancer Total Addressable Market (TAM)

6. Epithelial Ovarian Cancer Market Segmentation

6.1. Global Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Surgery
6.2. Global Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Platinum-based Chemotherapy Drugs
Poly(ADP-ribose) Polymerase Inhibitors
Bevacizumab
Chemotherapeutic Agents
6.3. Global Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Early Stage
Advanced Stage
6.4. Global Epithelial Ovarian Cancer Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Imaging
Biopsy
Blood Tests
6.5. Global Epithelial Ovarian Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Diagnostic Laboratories
6.6. Global Epithelial Ovarian Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Platinum-Based Chemotherapy
Non-Platinum Chemotherapy
Combination Chemotherapy
6.7. Global Epithelial Ovarian Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
PARP Inhibitors
Angiogenesis Inhibitors
Other Targeted Agents
6.8. Global Epithelial Ovarian Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Checkpoint Inhibitors
Cancer Vaccines
Adoptive T-Cell Therapy
6.9. Global Epithelial Ovarian Cancer Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Selective Estrogen Receptor Modulators (SERMs)
Aromatase Inhibitors
Progestins
6.10. Global Epithelial Ovarian Cancer Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Debulking Surgery
Oophorectomy
Hysterectomy
Other Surgical Procedures

7. Epithelial Ovarian Cancer Market Regional And Country Analysis

7.1. Global Epithelial Ovarian Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Epithelial Ovarian Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Epithelial Ovarian Cancer Market

8.1. Asia-Pacific Epithelial Ovarian Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Epithelial Ovarian Cancer Market

9.1. China Epithelial Ovarian Cancer Market Overview
9.2. China Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Epithelial Ovarian Cancer Market

10.1. India Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Epithelial Ovarian Cancer Market

11.1. Japan Epithelial Ovarian Cancer Market Overview
11.2. Japan Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Epithelial Ovarian Cancer Market

12.1. Australia Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Epithelial Ovarian Cancer Market

13.1. Indonesia Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Epithelial Ovarian Cancer Market

14.1. South Korea Epithelial Ovarian Cancer Market Overview
14.2. South Korea Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Epithelial Ovarian Cancer Market

15.1. Western Europe Epithelial Ovarian Cancer Market Overview
15.2. Western Europe Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Epithelial Ovarian Cancer Market

16.1. UK Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Epithelial Ovarian Cancer Market

17.1. Germany Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Epithelial Ovarian Cancer Market

18.1. France Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Epithelial Ovarian Cancer Market

19.1. Italy Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Epithelial Ovarian Cancer Market

20.1. Spain Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Epithelial Ovarian Cancer Market

21.1. Eastern Europe Epithelial Ovarian Cancer Market Overview
21.2. Eastern Europe Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Epithelial Ovarian Cancer Market

22.1. Russia Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Epithelial Ovarian Cancer Market

23.1. North America Epithelial Ovarian Cancer Market Overview
23.2. North America Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Epithelial Ovarian Cancer Market

24.1. USA Epithelial Ovarian Cancer Market Overview
24.2. USA Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Epithelial Ovarian Cancer Market

25.1. Canada Epithelial Ovarian Cancer Market Overview
25.2. Canada Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Epithelial Ovarian Cancer Market

26.1. South America Epithelial Ovarian Cancer Market Overview
26.2. South America Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Epithelial Ovarian Cancer Market

27.1. Brazil Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Epithelial Ovarian Cancer Market

28.1. Middle East Epithelial Ovarian Cancer Market Overview
28.2. Middle East Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Epithelial Ovarian Cancer Market

29.1. Africa Epithelial Ovarian Cancer Market Overview
29.2. Africa Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Epithelial Ovarian Cancer Market Competitive Landscape And Company Profiles

30.1. Epithelial Ovarian Cancer Market Competitive Landscape
30.2. Epithelial Ovarian Cancer Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Epithelial Ovarian Cancer Market Other Major And Innovative Companies

31.1. Bayer AG
31.2. Bristol-Myers Squibb Company
31.3. AstraZeneca PLC
31.4. GlaxoSmithKline plc
31.5. Eli Lilly and Company
31.6. Boehringer Ingelheim GmbH
31.7. Merck KGaA
31.8. Siemens Healthineers AG
31.9. Quest Diagnostics Incorporated
31.10. Eisai Co. Ltd.
31.11. Genentech Inc.
31.12. Qiagen N.V.
31.13. Myriad Genetics Inc.
31.14. Zymeworks Inc.
31.15. Novogen Limited

32. Global Epithelial Ovarian Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Epithelial Ovarian Cancer Market

34. Recent Developments In The Epithelial Ovarian Cancer Market

35. Epithelial Ovarian Cancer Market High Potential Countries, Segments and Strategies

35.1 Epithelial Ovarian Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 Epithelial Ovarian Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 Epithelial Ovarian Cancer Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer